

## Synthetic Curcumin Derivatives Inhibit Jun-Fos-DNA Complex Formation

Hyun-Kyung Kim and Chul-Hak Yang\*

School of Chemistry, College of Natural Sciences, Seoul National University, Seoul 151-747, Korea

Received May 17, 2004

Jun/Fos, a crucial factor in transmitting the tumor-promoting signal from the extracellular environment to the nuclear transcription machinery, has a dimerization interface possessing several coiled structural properties. Jun and Fos can interact with the DNA regulatory region, AP-1 (Activator Protein-1), which is composed of 5'-TGAC/GTCA-3'.<sup>1</sup> Curcumin is a well-known anticancer and anti-inflammatory compound.<sup>2,3</sup> It also acts as an inhibitor of the Jun-Fos function. c-Fos and c-Jun with a bZIP region are overexpressed in BL21 *E. coli* and purified with an Ni<sup>2+</sup> affinity column. The inhibitors of Fos-Jun-AP-1 complex formation were searched through the EMSA (electrophoresis mobility shift assay) experiment, and new curcuminoids were synthesized and investigated as to their inhibitory effect on the same system. Two curcuminoids showed a stronger inhibitory effect than curcumin. This inhibitory activity was quantified with EMSA. 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (BJC003) and 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC005) showed remarkably high inhibitory activities. IC<sub>50</sub> of 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (BJC003) and 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC005) are 8.98  $\mu$ M and 5.40  $\mu$ M, respectively. However, 1,7-bis(4-methyl-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC004) did not show inhibitory activity.

**Key Words :** Curcumin, Jun-Fos-AP-1 complex, 1,7-Bis(4-methyl)-1,6-heptadiene-3,5-dione (BJC003), 1,7-Bis(4-methyl-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC004), 1,7-Bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC005)

### Introduction

A variety of processes have evolved in eukaryotic cells for coupling environmental cues to the selective regulation of gene expression. Cell surface stimuli evoke a series of intracellular signals that ultimately affect the levels or activities of proteins that bind to transcriptional control elements. Many of these transcription factors interact with DNA in the form of dimeric complexes that employ a limited set of defined structural motifs.<sup>4</sup> These conserved domains mediate interactions that generate an array of heterodimeric protein complexes formed from the products of related gene family members. In many cases, protein dimers may have distinct transcriptional properties although they exhibit similar DNA-binding specificities. The class of transcription factors that contain the leucine zipper motif exemplifies this phenomenon.<sup>5</sup> They include SV40, the human metallothionein IIa gene, and the control regions of genes whose expression is stimulated by treatment of cells with the phorbol ester, a tumor promoting agent. A number of AP-1-related reports suggest that over-expression, irregularity, and transformation could induce tumor progression and cancer-cell growth.<sup>6</sup> AP-1 has two oncogene products with its own components, namely, Jun and Fos. In this report, in order to search for a more potent Fos/Jun inhibitor, we synthesized a series of symmetrical curcumin analogs by Pabons method<sup>2</sup> and tested their inhibitory activity by performing gel-retardation assay.

### Experimental Sections

**Reagents.** Chemicals for synthesis and all other reagents and solvents were purchased from Sigma-Aldrich Chemical Co. or TCI (Tokyo, Japan). The *wb-fos*, *wb-jun*, *pTK-fos* and *pTK-jun* genes were kindly provided by Dr. T. Curran, St. Jude Children Hospital.

**Synthesis of curcumin derivatives.** For synthesis of 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (BJC003), according to the reported method,<sup>2</sup> 4-methyl-benzaldehyde (2.68 g, 0.02 mole) and tributyl borate (1.11 g, 0.055 mole) were dissolved in 10 mL of dry ethyl acetate and were heated to 100 °C. Subsequently the reaction product from 1.099 mL of 2,4-pentadione and 0.5 g boric anhydride (0.07 mole) was added and the mixture heated for 30 min, while stirring, in order to achieve a homogeneous mixture. After cooling to 85 °C, 0.05 mL of butylamine was added every 5 min (total 0.2 mL). Finally, after having been maintained for 30 min at 100 °C, while stirring, the mixture turned brown. After cooling to 50 °C, 15 mL of 0.4 N hydrochloric acid (60 °C) was added, the mixture was then stirred for another 30 min, after which 20 mL of ethyl acetate was added. The layers were separated, and the aqueous layer was extracted once with 5 mL of ethyl acetate. The combined ethyl acetate layers were washed acid-free, dried over magnesium sulfate and evaporated. The residue was dissolved in chloroform/methanol (2 : 1) and subsequently cooled, after which the crystals were sucked off. With the same method, 1,7-bis(4-methyl-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC004) was also obtained by the same synthetic method. The residue was

\*Corresponding Author. e-mail: chulyang@plaza.snu.ac.kr


dissolved in methylene chloride/methanol (2 : 1) and subsequently cooled, after which the crystals were sucked off.

Also applying the same method, 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC005) was obtained. The residue was dissolved in DMSO/methylene chloride (1 : 1.5) and subsequently cooled. After that the solution was extracted once with 5 mL of ethyl acetate and evaporated.

**Instrumental analysis.**  $^1\text{H}$  NMR spectra were recorded with TMS as an internal standard at 300 MHz on a BRUKER AVANCE DPX-300 NMR spectrometer. HREIMS data were taken with a JEOL JMS AX505WA mass spectrometer operating at 70 eV. The melting point was

measured with a Thomas-Hoover melting point apparatus (6427-H10). TLC analysis was performed with Merck Silica gel 60 F<sub>254</sub> plates (No. 1.05554). For column chromatography, Merck Silica gel 60 (230-400 mesh) was employed.<sup>7</sup>

**Expression and purification of wb-Fos<sup>5</sup> and pTK-Jun<sup>8</sup>.** *c-fos* and *c-jun* in plasmid were over-expressed in an *E. coli* strain BL21 (DE3) using isopropyl  $\beta$ -D-thiogalactopyranoside induction (final concentration 1.0 mM) as fusion proteins containing six histidine residues at the N-terminal. The pelleted cells were then solubilized in the presence of 6 M guanidine hydrochloride at 1/25 th of the volume of the original culture volume containing protease inhibitor cocktail tablets (Complete<sup>TM</sup>, Mini, EDTA-free, Roche (BM)), and then they were briefly sonicated. The proteins



	BJC003	BJC004	BJC005
a	-H	-NO <sub>2</sub>	-NO <sub>2</sub>
b	-CH <sub>3</sub>	-CH <sub>3</sub>	-OH
c	-H	-H	-OCH <sub>3</sub>

**Scheme 1.** Synthesis of curcumin derivatives

were purified by nickel-chelated affinity chromatography (His•bind<sup>®</sup> Resin, Novagen) in the presence of guanidine and refolded by extensive dialysis against a dialysis buffer (50 mM NaCl, 25 mM Tris-HCl, 1 mM EDTA, 1 mM DTT pH 7.4).

**Labeling and purification of AP-1 DNA.** Radiolabeled DNA probe was prepared by 3.5 pmole of AP-1 consensus oligonucleotide (Promega) with 10  $\mu$ Ci [ $\gamma$ -<sup>32</sup>P]ATP (Amersham pharmacia) and T4 polynucleotide kinase (TAKARA) and efficiently removed precursor from DNA labeled by Quick Spin G-25 Sephadex columns (Boehringer Mannheim).

**EMSA (Gel retardation assay).** A DNA binding reaction was carried out by mixing 5  $\mu$ L Fos-Jun heterodimeric complex and 0.2  $\mu$ Ci probe DNA in a gel shift buffer (20% glycerol, 5 mM EDTA, 2.5 mM DTT, 25 mM NaCl, 50 mM Tris-HCl (pH 7.5), 0.01 mg/mL poly(dI-dC)). After one hour incubation at room temperature, 10  $\times$  loading buffer (DNA binding buffer with bromophenol blue dye) was added. Samples were resolved on a 6% nondenatured gel (5  $\times$  TBE 0.70 mL, 20% acryl-bis (80 : 1) 2.1 mL, 95% glycerol 0.21 mL, ddH<sub>2</sub>O 3.75 mL, 1.5% APS 0.35 mL, TEMED 15  $\mu$ L) in 0.5  $\times$  TBE buffer. The gel was prepared at 100 volts for 1-1.5 hrs, then with a circulating buffer and run at 120 volts until no more bromophenol blue dye was passed out. The retarded gel was wrapped with a vinyl envelope, placed against a piece of X-ray film, and underwent an autoradiogram exposure overnight at -70  $^{\circ}$ C. The exposed film was then developed and fixed.

## Results and Discussion

**Synthesis of curcumin derivatives.** The preparation of curcumin derivatives BJC003, BJC004 and BJC005 is shown in Scheme 1 and has been reported in detail elsewhere.<sup>2</sup>

**1,7-Bis(4-methyl)-1,6-heptadiene-3,5-dione (BJC003)**  
The yield is 2.11 g (70%) consisting of bright yellow powder, mp 209-210  $^{\circ}$ C; <sup>1</sup>H NMR: (CDCl<sub>3</sub>)  $\delta$  2.38 (s, 6H, 2  $\times$  CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>-), 5.84 (s, 1H, =CH<sub>a</sub>-), 6.60 (d, J = 13 Hz, 2H, 2  $\times$  -CH<sub>b</sub>=CH<sub>c</sub>-), 7.35 (m, 6H, 2  $\times$  -C<sub>6</sub>H<sub>4</sub>-), 7.66 (d, J = 13 Hz, 2H, 2  $\times$  -CH<sub>c</sub>=CH<sub>b</sub>-). HREIMS m/z calcd for C<sub>21</sub>H<sub>20</sub>O<sub>2</sub> 304.1463 obsd 304.1469 (Fig. 1).


**1,7-Bis(4-methyl-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC004)**  
The yield is 2.16 g (55%) consisting of yellow powder, mp 234-235  $^{\circ}$ C; <sup>1</sup>H NMR: (CDCl<sub>3</sub>)  $\delta$  2.66 (s, 6H, 2  $\times$  CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>-), 5.90 (s, 1H, =CH<sub>a</sub>-), 6.70 (d, J = 13 Hz, 2H, 2  $\times$  -CH<sub>b</sub>=CH<sub>c</sub>-), 7.58 (m, 6H, 2  $\times$  -C<sub>6</sub>H<sub>3</sub>-), 8.19 (d, J = 13 Hz, 2H, 2  $\times$  -CH<sub>c</sub>=CH<sub>b</sub>-). HREIMS m/z calcd for C<sub>21</sub>H<sub>18</sub>O<sub>6</sub>N<sub>2</sub> 394.1165, obsd 398.1157 (Fig. 2).

**1,7-Bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC005)**  
The yield is 0.5 g (10%) consisting of brownish red powder, mp decomposed at 220  $^{\circ}$ C; <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>)  $\delta$  6.13 (s, 1H, =CH<sub>a</sub>-), 6.98 (d, 2H, 2  $\times$  -CH<sub>b</sub>=CH<sub>c</sub>-), 7.8 (s, 2H, 2  $\times$  -C<sub>6</sub>H<sub>4</sub>-), 7.6 (s, 2H, 2  $\times$  -CH<sub>c</sub>=CH<sub>b</sub>-), 3.95 (s, 2  $\times$  OCH<sub>3</sub>), HREIMS m/z calcd for C<sub>21</sub>H<sub>18</sub>O<sub>10</sub>N<sub>2</sub> 458.0961, obsd 458.0982 (Fig. 3).


**Establishment of Jun-Fos assay system (Fos-Jun-AP-1**

**complex).** We established an assay system to screen the inhibitors against Fos-Jun-DNA complex formation. This system comprises a gel retardation assay, which contains the Fos/Jun dimer, radio-labeled AP-1 DNA, and inhibitor. If curcumin derivatives inhibit the formation of complex, a decrease in the band of retardation can be observed on X-ray film.

Jun and Fos proteins induced by IPTG were overexpressed in *E. coli* BL21<sup>9,10</sup> and Jun and Fos proteins were clearly shown at nearly 14 kDa and 15 kDa. Both proteins were efficiently expressed in *E. coli* and were found in the soluble fraction of the crude cell lysate.<sup>10</sup> However, Fos was easily cracked by sonication and enzymatic lysis. We could obtain intact Fos in 8 M-guanidine solution. The proteins were purified from the clarified cell lysate in a single step as described under "His-Bind Kits" from Novagen.<sup>11,12</sup> They




**Figure 1.** <sup>1</sup>H NMR spectrum of 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (BJC003) (a), Mass spectrum of 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (BJC003) (b).



**Figure 2.** <sup>1</sup>H NMR spectrum of 1,7-bis(4-methyl-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC004) (a), Mass spectrum of 1,7-bis(4-methyl-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC004) (b).


were >95% homogeneous as determined by SDS-PAGE. The concentrations of proteins were determined by Bradford assay. The concentrations of purified Jun and Fos were 129  $\mu$ L/mL and 36.74  $\mu$ L/mL, respectively. Purified Jun and Fos heterodimerize to form Jun-Fos-AP-1 complex with 20 mM DTT. We could identify Jun-Fos-AP-1 complex in low concentration on EMSA but Jun-Jun-AP-1 and Fos-Fos-AP-1 complex could not be identified in low concentration. On the other hand, broken Fos was also purified and formed Jun-Fos-AP-1 complex. All of them could form complex with high efficiency when DTT was added.

**Inhibitory effect of curcumin derivatives on EMSA (gel retardation assay).** We investigated how some curcumin derivatives inhibit the formation of Fos-Jun-DNA




**Figure 3.** <sup>1</sup>H NMR spectrum of 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC005) (a), MS spectrum of 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC005) (b).

complex. Especially 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (BJC003) and 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC005) were confirmed as remarkably potent inhibitors of Jun-Fos-AP-1 complex. The activity was quantified with a liquid scintillation counter by checking the corresponding band. The activities of those compounds are shown in Figures 4 and 5. IC<sub>50</sub>, 50% inhibition concentration of 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (BJC003) and 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC005), were 8.98  $\mu$ M and 5.40  $\mu$ M, respectively. Remarkably, BJC005 exhibits a much greater inhibitory effect than momordin, reported hitherto as the best Fos-Jun-DNA complex inhibitor<sup>1</sup> (Figure 8). However, BJC004 did not exhibit any inhibitory activity against Fos-Jun-DNA complex formation




**Figure 4.** Inhibitory effect of 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (BJC003) on EMSA. The positions of unbound DNA and purified Fos-Jun-DNA complex are indicated.  $^{32}\text{P}$ -radiolabeled AP-1 DNA was used. All inhibitors were dissolved in DMSO and used in 0.44 mM. The concentrations of Fos-Jun heterodimer and DNA are 0.191  $\mu\text{M}$  and 0.194 nM, respectively. Lane 1: positive control (DMSO instead of inhibitor), Lane 2: 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (13.3  $\mu\text{M}$ ), Lane 3: 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (25  $\mu\text{M}$ ), Lane 4: 1,7-bis(4-methyl)-1,6-heptadiene-3,5-dione (50  $\mu\text{M}$ ).



**Figure 5.** Inhibitory effect of 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC005) on EMSA. Lane 1: positive control, Lane 2: 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (4  $\mu\text{M}$ ), Lane 3: 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (40  $\mu\text{M}$ ), Lane 4: 1,7-bis(4-hydroxy-5-methoxy-3-nitrophenyl)-1,6-heptadiene-3,5-dione (400  $\mu\text{M}$ ).

(Fig. 6). In the same system, the  $\text{IC}_{50}$  values of curcumin and momordin are 480  $\mu\text{M}$  and 186  $\mu\text{M}$ , respectively. On the other hand, 1,7-bis(4-methyl-3-nitrophenyl)-1,6-heptadiene-3,5-dione (BJC004) did not show inhibitory activity for Jun-Fos-AP-1 complex (Fig. 6). A slight modification of the benzaldehyde moiety in the curcumin analogs structure affected the inhibition of Fos-Jun and DNA complex formation. Our data showed that the polarity of the substituted group acts as a parameter of inhibition. In other



**Figure 6.** Comparison of inhibitory effect. Lane 1: Positive control, Lanes 2: momordin, Lanes 3: curcumin, Lanes 4: BJC 003 (0.2 mM), Lane 5: BJC004 (0.2 mM), Lane 6: BJC005 (0.2 mM).

words, *p*-position- and polar-group-substituted curcumin analogs have a tendency to inhibit the Fos-Jun-DNA complex formation more potently. Since we lack of a complete understanding of the inhibitory action of curcumin analogs, we could not clearly explain these results. However, we suggest that many substitutions of polar groups to benzene rings offer a richly negative charge to the molecule itself, so they become potent competitors to DNA for interaction with the protein. Insertion of a nitro group into the benzene ring might contribute to improve the inhibitory activity.

These curcumin analogs showing high inhibitory activities can be utilized to define the inhibition of the cancer-related transcription factor, Fos-Jun heterodimer, and to design a potent anticancer agent. Therefore, this structural information provides crucial clues for further studies. Judging from the chemical genomics, these curcumin analogs could also serve as the best intermediaries for achieving a complete understanding of the intracellular function of Fos-Jun heterodimer.

## Conclusions

We succeeded in establishing the basis of a superior assay system with pure Jun and Fos and the synthesis of curcumin derivatives with an inhibitory effect for Jun-Fos-AP-1 complex. Their inhibitory activities were also shown to be stronger than curcumin and momordin. Jun and Fos including a His-tag could be purified by an  $\text{Ni}^{2+}$  column. Moreover, they can be dimerized in the optimized buffer solution. Curcumin derivatives were well synthesized by a high-temperature method as compared with the room-temperature method published by H. J. J. Pabon.<sup>2</sup> Two curcumin derivatives showed higher activity than curcumin on EMSA.

In summary, our results clearly demonstrated that synthesized curcumin analogs, such as BJC003 and BJC004 show

more potent inhibitory activities against Fos-Jun-DNA complex formation than curcumin and momordin. Further study is required to determine the precise molecular mechanism of inhibition by curcuminoids.

**Acknowledgements.** This work was supported by the Korea Research Foundation Grant (KRF-2001-015-DP0344). Financial support in part from the Brain Korea 21 Program to Hahm and Park is gratefully acknowledged.

### References

1. Lee, D. K., *et al.* *Anticancer Research* **1998**, *18*, 119-124.
  2. Pabon, H. J. *J. Recl. Trav. Chim. Pays-Bas* **1964**, *83*, 379-386.
  3. Toshiya, M.; Akiko, J. *J. Agric. Food Chem.* **1994**, *42*, 1850-1856.
  4. Cory, A.; Daniel, L.; Tom, C. *Molecular and Cellular Biology* **1991**, *11*, 3624-3632.
  5. Abate, C.; Luk, D.; Gentz, R.; Rauscher, F. J.; Curran, T. *Pro. Natl. Acad. Sci. USA* **1990**, *87*, 1032-1036.
  6. Angel, P. E.; Herrlich, P. A. *The Fos and Jun Families of Transcription Factors*; CRC press: U.S.A., 1994; pp 169-286.
  7. Smith, P. K.; Krohn, R. I.; Hermanson, G. T.; Mallia, A. K.; Gartner, F. H.; Provenzano, M. D.; Fujimoto, E. K.; Goeke, N. M.; Olson, B. J.; Klenk, D. C. *Anal. Biochem.* **1985**, *150*, 76-85.
  8. Kerppola, T. K.; Curran, T. *Cell* **1991**, *66*, 317-326.
  9. Salvatore, S.; Anna, M.; Bruno, M.; Luciano, D. C.; Gabriele, D.; Rocco, D. P.; Francesco, B.; Massimo, L.; Arduino, O. *Biochimica et Biophysica Acta* **1999**, *1430*, 103-110.
  10. Silvia, V.; Alessandra, C.; Jan, N.; Kirk, S.; Mauro, G.; Alberto, V. *Protein Expression and Purification* **1999**, *15*, 8-15.
  11. Qi, H.; Liping, W.; Michael, F.; Carlos, E. C. *The Journal of Biological Chemistry*; **1999**, *274*, 15305-14314.
  12. Slawomir, D.; Jozef, K. *Protein Expression and Purification* **1999**, *16*, 96-102.
  13. Lullien-Pellerin, V., *et al.* *Eur. J. Biochem.* **1999**, *260*, 861-868.
-